

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

October 18, 2023

Chordia named “Judges' Special Award”
at Japan Healthcare Venture Summit 2023

Kanagawa, Japan,

October 18, 2023 – Chordia participated in the Japan Healthcare Venture Summit 2023 held on October 11-13, 2023.

At the JHVS Venture Award 2023, one of the events, Chordia made a presentation on "Development of Anticancer Drugs Targeting RNA Regulatory Stress" and received the Judges' Special Award.

About the Japan Healthcare Venture Summit 2023

The Summit is organized by the Ministry of Health, Labor, and Welfare (MHLW) to provide a venue for medical ventures to exhibit booths and make presentations to promote matching and networking with key persons from major companies, financial institutions, research institutions, etc., and to create an environment to deepen understanding of regulations and associated systems and efforts to support ventures. The MHLW holds these events to create an environment to deepen understanding of the current state of regulations and related systems and venture support efforts among associated parties.

About the JHVS Venture Award 2023

The award aims to encourage medical ventures to rise to the challenge and create innovative innovations. Chordia received the award for its excellent seeds of usefulness, business planning, and growth potential in the research and development of anti-cancer drugs targeting RNA-regulated stress.

About Chordia Therapeutics

Chordia is a clinical stage biotech company based in Fujisawa, Kanagawa Prefecture, Japan, engaged in the research and development of novel therapies for cancers.

Chordia's lead asset CLK inhibitor CTX-712 is under Phase 1 clinical study in Japan. CTX-712 potentially targets the vulnerability of cancer, and is expected to deliver benefit to patients of various types of cancer. In addition to CTX-712, Chordia is engaged in the research of several preclinical assets, including CTX-439, a CDK12 inhibitor, which is expected to be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

info@chorditherapeutics.com



Established: November 2017
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,
Kanagawa 251-0012, Japan
Representative: Hiroshi Miyake, Representative Director
Website: <https://www.chorditherapeutics.com/en/>

For more information, contact IR Mizobe: ir@chorditherapeutics.com